$9.235
+0.08
(+0.93%)▲
Insights on Pharming Group Nv
Revenue is up for the last 11 quarters, 44.63M → 81.86M (in $), with an average increase of 5.6% per quarter
Netprofit is down for the last 3 quarters, 3.46M → -2.72M (in $), with an average decrease of 89.3% per quarter
In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 96.5%
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 260.2%
3.79%
Downside
Day's Volatility :6.32%
Upside
2.63%
5.74%
Downside
52 Weeks Volatility :47.88%
Upside
44.7%
Period | Pharming Group Nv | Index (Russel 2000) |
---|---|---|
3 Months | -21.67% | 0.0% |
6 Months | -18.2% | 0.0% |
1 Year | -20.87% | 0.0% |
3 Years | -25.06% | -22.6% |
Market Capitalization | 616.2M |
Book Value | $0.31 |
Earnings Per Share (EPS) | -0.16 |
Profit Margin | -4.18% |
Operating Margin TTM | -29.35% |
Return On Assets TTM | -3.53% |
Return On Equity TTM | -5.32% |
Revenue TTM | 258.4M |
Revenue Per Share TTM | 3.91 |
Quarterly Revenue Growth YOY | 30.7% |
Gross Profit TTM | 188.1M |
EBITDA | -14.3M |
Diluted Eps TTM | -0.16 |
Quarterly Earnings Growth YOY | -0.61 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 176.8M | ↑ 43.77% |
Net Income | 32.7M | ↓ 129.8% |
Net Profit Margin | 18.5% | ↑ 107.72% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 212.1M | ↑ 22.49% |
Net Income | 45.4M | ↑ 41.82% |
Net Profit Margin | 21.41% | ↑ 2.91% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 280.9M | ↑ 20.63% |
Net Income | 46.4M | ↓ 6.9% |
Net Profit Margin | 16.53% | ↓ 4.88% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 215.0M | ↓ 16.88% |
Net Income | 18.1M | ↓ 57.62% |
Net Profit Margin | 8.43% | ↓ 8.1% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 220.3M | ↑ 8.31% |
Net Income | 14.6M | ↓ 14.52% |
Net Profit Margin | 6.65% | ↓ 1.78% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 245.3M | ↑ 19.3% |
Net Income | -10.5M | ↓ 177.14% |
Net Profit Margin | -4.3% | ↓ 10.95% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 58.5M | ↑ 0.71% |
Net Income | -15.7M | ↓ 260.75% |
Net Profit Margin | -26.78% | ↓ 43.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 59.6M | ↑ 0.0% |
Net Income | -16.0M | ↑ 0.0% |
Net Profit Margin | -26.78% | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 59.9M | ↑ 0.51% |
Net Income | 1.4M | ↓ 109.02% |
Net Profit Margin | 2.4% | ↑ 29.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 66.7M | ↑ 21.43% |
Net Income | 3.5M | ↑ 162.62% |
Net Profit Margin | 5.2% | ↑ 2.8% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 81.9M | ↑ 22.81% |
Net Income | -2.7M | ↓ 178.58% |
Net Profit Margin | -3.33% | ↓ 8.53% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 81.9M | ↑ 0.0% |
Net Income | -2.7M | ↑ 0.0% |
Net Profit Margin | -3.33% | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 280.8M | ↑ 23.11% |
Total Liabilities | 200.0M | ↓ 1.14% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 286.4M | ↑ 4.15% |
Total Liabilities | 155.0M | ↓ 20.84% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 515.5M | ↑ 63.95% |
Total Liabilities | 289.5M | ↑ 70.11% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 449.5M | ↓ 5.3% |
Total Liabilities | 231.2M | ↓ 13.26% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 456.1M | ↑ 7.28% |
Total Liabilities | 236.9M | ↑ 8.31% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 462.9M | ↑ 8.7% |
Total Liabilities | 244.1M | ↑ 10.36% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 453.1M | ↑ 10.64% |
Total Liabilities | 239.6M | ↑ 22.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 464.3M | ↑ 0.66% |
Total Liabilities | 241.2M | ↓ 1.12% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 469.0M | ↑ 0.94% |
Total Liabilities | 250.3M | ↑ 3.74% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 436.5M | ↑ 1.55% |
Total Liabilities | 226.5M | ↓ 1.27% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 461.4M | ↑ 5.72% |
Total Liabilities | 242.2M | ↑ 6.94% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 471.0M | ↑ 2.07% |
Total Liabilities | 252.2M | ↑ 4.1% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 52.8M | ↑ 0.75% |
Investing Cash Flow | -4.3M | ↓ 37.65% |
Financing Cash Flow | -23.5M | ↑ 426.13% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 83.5M | ↑ 61.42% |
Investing Cash Flow | -28.2M | ↑ 569.06% |
Financing Cash Flow | -69.8M | ↑ 203.33% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 111.9M | ↑ 22.03% |
Investing Cash Flow | -16.8M | ↓ 45.76% |
Financing Cash Flow | 80.4M | ↓ 204.82% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 40.9M | ↓ 60.29% |
Investing Cash Flow | -20.3M | ↑ 31.33% |
Financing Cash Flow | -30.2M | ↓ 140.84% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 24.5M | ↓ 36.62% |
Investing Cash Flow | 5.7M | ↓ 129.63% |
Financing Cash Flow | -5.3M | ↓ 81.33% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 6.1M | ↓ 55.03% |
Investing Cash Flow | -427.4K | ↑ 33.89% |
Financing Cash Flow | 297.8K | ↓ 114.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 6.2M | ↑ 0.0% |
Investing Cash Flow | -234.5K | ↓ 46.12% |
Financing Cash Flow | 303.2K | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.5M | ↓ 269.56% |
Investing Cash Flow | 22.2M | ↓ 9546.05% |
Financing Cash Flow | -2.9M | ↓ 1045.68% |
Sell
Neutral
Buy
Pharming Group Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Pharming Group Nv | -5.04% | -18.2% | -20.87% | -25.06% | -44.7% |
Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Pharming Group Nv | NA | NA | NA | 0.0 | -0.05 | -0.04 | NA | 0.31 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Pharming Group Nv | Buy | $616.2M | -44.7% | NA | -4.18% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Silverberg Bernstein Capital Management LLC
Organization | Pharming Group Nv |
Employees | 382 |
CEO | Dr. Sijmen de Vries M.B.A., M.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$9.24
+0.93%
Keyarch Acquisition Corp
$9.24
+0.93%
Connexa Sports Technologies Inc
$9.24
+0.93%
Us Value Etf
$9.24
+0.93%
First Wave Biopharma Inc
$9.24
+0.93%
Global X Msci Next Emerging
$9.24
+0.93%
Fat Projects Acquisition Corp
$9.24
+0.93%
Capital Link Global Fintech
$9.24
+0.93%
Applied Uv Inc
$9.24
+0.93%